300. IgG4関連疾患 IgG4-related disease Clinical trials / Disease details
臨床試験数 : 40 / 薬物数 : 47 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200062904 | 2022-08-23 | 2022-08-23 | A multicenter, randomized, open-label clinical study on the efficacy and safety of iguratimod in the treatment of IgG4-related diseases | A multicenter, randomized, open-label clinical study on the efficacy and safety of iguratimod in the treatment of IgG4-related diseases | IgG4-related disease | glucocorticoid monotherapy group:glucocorticoid monotherapy;glucocorticoid combined with iguratimod group:glucocorticoid combined with iguratimod 25 mg bid; | Beijing Friendship Hospital Affiliated to Capital Medical University | NULL | Recruiting | 18 | 100 | Both | glucocorticoid monotherapy group:122;glucocorticoid combined with iguratimod group:122; | Phase 4 | China |
| 2 | NCT03368274 (ClinicalTrials.gov) | September 1, 2017 | 20/9/2017 | To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom | To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom | IgG4-related Disease | Drug: T 614 | Wen Zhang | NULL | Unknown status | 18 Years | 70 Years | All | 30 | Phase 4 | China |